SG Americas Securities LLC Has $16.64 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

SG Americas Securities LLC lifted its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 4,022.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 597,993 shares of the company’s stock after purchasing an additional 583,486 shares during the period. SG Americas Securities LLC owned 0.86% of Akero Therapeutics worth $16,636,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AKRO. Mirae Asset Global Investments Co. Ltd. grew its holdings in Akero Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after acquiring an additional 446 shares during the last quarter. Eastern Bank acquired a new position in shares of Akero Therapeutics during the third quarter worth approximately $100,000. Summit Financial Wealth Advisors LLC bought a new stake in shares of Akero Therapeutics during the third quarter valued at approximately $205,000. Victory Capital Management Inc. acquired a new stake in shares of Akero Therapeutics in the third quarter valued at approximately $211,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Akero Therapeutics in the 3rd quarter worth approximately $265,000.

Akero Therapeutics Stock Up 4.6 %

Shares of Akero Therapeutics stock opened at $26.16 on Friday. The business has a fifty day simple moving average of $28.58 and a 200 day simple moving average of $28.06. The stock has a market cap of $1.83 billion, a PE ratio of -6.98 and a beta of -0.19. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 12 month low of $15.32 and a 12 month high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Research analysts predict that Akero Therapeutics, Inc. will post -3.96 EPS for the current year.

Insider Buying and Selling at Akero Therapeutics

In related news, insider Catriona Yale sold 4,515 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $32.53, for a total value of $146,872.95. Following the completion of the sale, the insider now owns 74,158 shares in the company, valued at $2,412,359.74. This represents a 5.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $28.03, for a total value of $280,300.00. Following the transaction, the chief operating officer now owns 218,083 shares in the company, valued at approximately $6,112,866.49. This represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 262,135 shares of company stock valued at $8,223,000. Corporate insiders own 7.94% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a research report on Thursday, January 16th. Citigroup initiated coverage on Akero Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.83.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.